Sepsis and coagulation

Current Opinion in Critical Care

Volumn 11, Issue 5, 2005, Pages 454-460

  Diehl, J L ^a,b   Borgel, D ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Activated protein C; Protein C; Protein S; Sepsis; Tissue factor

Indexed keywords

PROTEIN C; PROTEIN S; PROTEINASE ACTIVATED RECEPTOR 1; THROMBOMODULIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

BLOOD CLOTTING; COMPLEX FORMATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPSIS; THROMBOCYTE;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; FIBRINOLYSIS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS;

EID: 26944501971     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000176692.03186.e7     Document Type: Review

References (52)

1. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
2. Van der Wouwer M, Collen D, Conway EM. Thrombomodulin-Protein C-EPCR system. Integrated to regulate coagulation and inflammation. Arteriscler Thromb Vasc Biol 2004; 24:1374-1383.
3. Morboeuf O, Borgel D, Gaussem P, et al. Characterization of cleaved plasma protein S with a monoclonal antibody-based assay. Thromb Haemost 2000; 84:604-610.
4. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276:15567-15570.
5. Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276:11199-11203.
6. Yuksel M, Okajima K, Uchiba M, et al. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88:267-273.
7. Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
8. Isermann B, Sood R, Pawlinski R, et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med 2003; 9:331-337.
9. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70.
10. Domotor E, Benzakour O, Griffin JH, et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003; 101: 4797-4801.
11. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1: 1343-1348.
12. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196:565-577.
13. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9:338-342.
14. Perez-Casal M, Downey C, Fukudome K, et al. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005; 105:1515-1522. The authors describe a new form of EPCR and APC-containing microparticles able to exert anticoagulant activity. Moreover, APC induces the release of these potentially beneficial microparticles.
15. Mosnier LO, Gale AJ, Yegneswaran S, et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004; 104: 1740-1744. Utilization of such variants could prevent hemorrhagic complications of APC with preserved antiapoptotic and antiinflammatory functions.
16. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependant sphingosme 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178-3184. This is the first description of the intracellular signaling pathways explaining the differential PAR1-mediated cellular effects of protein C and FIIa. This study opens the way for future therapeutic developments.
17. Camerer E, Coughlin SR. APC signaling: tickling PAR1 for barrier protection? Blood 2005; 105:3004-3005.
18. Nan B, Lin P, Lumsden AB, et al. Effects of TNF-a and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res 2005; 115:417-426.
19. Hoffmann JN, Vollma B, Laschke MW, et al. Microhemodynamic and cellular mechanisms of activated protein C during endotoxemia. Crit Care Med 2004; 32:1011-1017.
20. Iba T, Kidokoro A, Fukunaga M, et al. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33:368-372.
21. Yamaji K, Wang Y, Liu Y, et al. Activated protein C, a natural anticoagulant protein, has antioxydant properties and inhibits lipid peroxydation and advanced glycation end products formation. Thromb Res 2005; 115:319-325.
22. Kask L, Trouw LA, Dahlback B, et al. The C4b-binding Protein-Protein S complex inhibits the phagocytosis of apoptotic cells. J Biol Chem 2004; 279: 23869-23873.
23. Bernardo A, Ball C, Nolasco L, et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104:100-106. This study explores a new mechanism linking inflammation and initiation of coagulation, implicating von Willebrand factor and ADAMTS13.
24. Washington AV, Schubert RL, Quigley L, et al. A TREM family member, TLT-1, is found exclusively in the α-granules of megakaryocytes and platelets. Blood 2004; 104:1042-1047.
25. Chen D, Giannopoulos K, Shiels PG, et al. Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood 2004; 104: 1344-1349.
26. Levi M. Cell surface-targeted anticoagulation in systemic infection and inflammation. Blood 2004; 104:1231-1232.
27. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104:3878-3885.
28. Mizgerd JP. APC: braking neutrophils to benefit patients? Blood 2004; 104: 3841.
29. Van der Poll T, Levi M, Nick JA, et al. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005; 171:1125-1128.
30. Kalil AC, Coyle SM, Um JY, et al. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004; 21:222-229.
31. Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood. Blood 2005; 105:2764-2770.
32. Egorina EM, Sovershaev MA, Bjorkoy G, et al. Intracellular and surface distribution of monocyte tissue factor. Application to intersubject variability. Arterioscler Thromb Vasc Biol 2005; 25:1-7.
33. Mattson E, Hartung T, Morath S, et al. Highly purified lipoteichoic acid from Staphylococcus aureus induces procoagulant activity and tissue factor expression in human monocytes but is a weak inducer in whole blood: comparison with peptidoglycan. Infect Immun 2004; 72:4322-4326.
34. Abraham E, Reinhart K, Svoboda P, et al. Efficacy and safety of Tifagocin (Recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-247.
35. Liaw PC, Esmon CT, Kahnamoui K, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104: 3958-3964. Mainly using protein C and APC dosages, arguments for an impaired process of protein C activation was found in 12 of 32 severe sepsis patients, with a negative correlation with survival. This study opens important perspectives for the respective utilizations of protein C and APC in severe sepsis.
36. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004; 2:1924-1933.
37. Angus DC, Laterre PF, Helterbrand J, et al. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 2004; 32:2199-2206.
38. Laterre PF, Levy H, Clermont G, et al. Hospital mortality and resource use in subgroups of the recombinant human activated Protein C worldwide evaluation in severe sepsis (PROWESS) trial. Crit Care Med 2004; 32: 2207-2218.
39. Macias WL, Vallet B, Bernard GR, et al. Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med 2004; 32:2385-2391.
40. Kinasewitz GT, Yan SB, Basson B, et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism. Crit Care 2004; 8:82-90.
41. Nilsson G, Astermark J, Lethagen S, et al. Protein C levels can be forcasted by global haemostatic tests in critically ill patients and predict long-term survival. Thromb Res 2005; 116:15-24.
42. Bakhtiari K, Meijers JCM, de Jonge E, et al. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416-2421. This study is the first prospective validation of the ISTH DIC scoring system in the critical care setting.
43. Dempfle CEH, Lorenz S, Smolinski M, et al. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascuiar coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 2004; 32:520-524.
44. Heslet L. Clinical implications of a validated scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2548-2549.
45. Yaguchi A, Lobo FLM, Vincent JL, et al. Platelet function in sepsis. J Thromb Haemost 2004; 2:2096-2102.
46. Levi M. Platelets at a crossroad of pathogenic pathways in sepsis. J Thromb Haemost 2004; 2:2094-2095.
47. Zenz W, Zoehrer B, Levin M, et al. Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study. Crit Care Med 2004; 32:1777-1780.
48. Hoffmann JN, Muhlbayer D, Jochum M, et al. Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis. Crit Care Med 2004; 32:1851-1859.
49. Warren BL, Eid A, Singer P, et al. High dose antithrombin III in severe sepsis, a randomized controlled trial. JAMA 2001; 286:1869-1878.
50. Wiedermann CJ. Improvement in coagulation markers with antithrombin. Beneficial in severe sepsis? Crit Care Med 2004.
51. Westendorp RGJ, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-563.
52. Hovinga JAK, Franco RF, Zago MA, et al. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease. J Thromb Haemost 2004; 2: 54-57.